Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen became CEO of Novo Nordisk in 2017 and has presided over the most transformative period in the company's century-long history. Novo Nordisk's GLP-1 receptor agonists — semaglutide, marketed as Ozempic for Type 2 diabetes and Wegovy for weight management — have created the largest new drug class in pharmaceutical history. These drugs produce dramatic weight loss (15-20% of body weight) while simultaneously reducing cardiovascular risk, transforming the treatment paradigm for both diabetes and obesity. The commercial success has been staggering: Novo Nordisk became Europe's most valuable company, surpassing LVMH, with a market capitalization exceeding $500 billion. Jørgensen faces the challenge of managing explosive demand that has chronically outstripped supply — Wegovy has experienced persistent shortages since launch. He has committed over $10 billion in manufacturing capacity expansion, building new production facilities across Denmark, the US, and France, while also investing in next-generation obesity drugs (including oral semaglutide and CagriSema, a combination GLP-1/amylin therapy promising even greater weight loss). Jørgensen's execution on manufacturing scale-up, next-generation pipeline progression (particularly CagriSema), and competitive positioning against Eli Lilly's Mounjaro/Zepbound are the critical drivers of Novo Nordisk's stock price. The total addressable market for obesity treatment is estimated at $100+ billion by 2030.